Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial

BackgroundDue to their potential impact on mood and wellbeing there has been increasing interest in the potential of serotonergic psychedelics such as N,N-dimethyltryptamine (DMT) in the treatment of major depressive disorder (MDD).AimThe aim of Part A of this study was to evaluate the safety, toler...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ellen James, David Erritzoe, Tiffanie Benway, Zelah Joel, Christopher Timmermann, Meghan Good, Claudio Agnorelli, Brandon M. Weiss, Tommaso Barba, Graham Campbell, Michelle Baker Jones, Charlotte Hughes, Helen Topping, Malcolm Boyce, Carol Routledge
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-01-01
coleção:	Frontiers in Psychiatry
Assuntos:	dimethyltryptamine major depressive disorder pharmacodynamic psychedelic safety tolerability
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1305796/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!